In the aftermath of Brexit, many investors have forgotten about the continuing shakeup in pharmaceuticals. The S&P Pharmaceuticals Select Industry Index has fallen by 28% in the last year, with prominent hedge funds losing particularly big on much-hyped Valeant (VRX:CN). According to SumZero cont...
![](https://sumzero-prod.s3.amazonaws.com/public/uploads/blog_post/featured_agn_83f0e23a3a.jpg)
Why Allergan is Not the Next Valeant
Published: July 07, 2016